.jpg)
3 hours ago
1
Article content
RIYADH, Saudi Arabia — In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreement to localize the manufacture of two biosimilar medicines within the Kingdom.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Article content
The signing ceremony took place at the Global Health Exhibition, under the auspices of the Ministry of Health and the Local Content & Government Procurement Authority, underscoring the Kingdom’s commitment to strengthening local manufacturing capabilities and ensuring reliable access to essential biologic therapies for patients nationwide.
Article content
Article content
Strengthening National Drug Security
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Through this agreement, Boston Oncology Arabia will lead the technology transfer, local manufacturing, and commercial rollout of two high-value biologics — adalimumab and etanercept — used in the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis. The initiative contributes to the continued expansion of the Kingdom’s pharmaceutical local content portfolio and advances Vision 2030’s objectives for healthcare transformation and industrial self-sufficiency.
Article content
“This signing represents a defining moment in the localization of complex biologics,” said Dr. Abdullah Baaj, Founder & CEO of Boston Oncology Arabia. “By manufacturing adalimumab and etanercept domestically, we are not only expanding access to life-changing biologic therapies, but also building a sustainable foundation for Saudi self-reliance in advanced pharmaceutical production.”
Article content
Eng. Abdulrahman bin Ibrahim Alsagheir, LCGPA’s Official Spokesperson, stated that “these agreements are expected to generate an estimated economic impact exceeding SAR 1.2 billion on the national GDP and create around 500 direct jobs to qualify Saudi talent in the healthcare and pharmaceutical sectors.”
Article content
A Milestone for Localized Biologic Manufacturing
Article content
Boston Oncology Arabia has been at the forefront of Saudi Arabia’s pharmaceutical local content strategy, with an expanding portfolio of advanced generics, biosimilars, peptides, and critical-care injectables designed to meet national demand across high-impact therapeutic areas. The company’s state-of-the-art manufacturing facility in Sudair Industrial City operates to USFDA, EMA, and SFDA standards, ensuring that every locally made product meets the highest international benchmarks for quality and safety.
Article content
The localization of these advanced biologics further solidifies Boston Oncology Arabia’s role as a national leader in biologic manufacturing, enabling faster, more reliable access to critical medicines and supporting the Kingdom’s long-term objective of pharmaceutical independence.
Article content
About Boston Oncology Arabia
Article content
Headquartered in Riyadh, Boston Oncology Arabia is a fully integrated pharmaceutical company purpose-built for localization. The company develops, manufactures, and commercializes advanced generics, biosimilars, peptides, and critical-care injectables to meet the highest global standards while serving the real-world needs of Saudi hospitals.
Article content
Article content
With operations anchored in Sudair Industrial City, Boston Oncology Arabia supports the goals of Vision 2030 by strengthening national drug security and expanding the Kingdom’s capacity for high-value, technology-driven pharmaceutical production. Its end-to-end model—spanning licensing, local development, manufacturing, and commercialization—ensures a reliable supply of world-class medicines that reach patients swiftly, safely, and affordably.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
For further information, please contact Boston Oncology Arabia Public Relations:
Article content
Article content
Article content
Article content
English (US)